Home Men's Health UK Assist awards funding to Oxford Vaccine Group for analysis into prevention of 5 epidemic threats

UK Assist awards funding to Oxford Vaccine Group for analysis into prevention of 5 epidemic threats

UK Assist awards funding to Oxford Vaccine Group for analysis into prevention of 5 epidemic threats


Oxford Vaccine Group (OVG), which led the fast medical improvement of the Oxford vaccine in COVID-19 within the pandemic, has been awarded a complete of £7,788,783 by UK Assist for analysis into the prevention of 5 harmful ailments with epidemic or pandemic potential. The awards will fund analysis into vaccines in opposition to:

  • Chikungunya and mayaro virus
  • Marburg virus
  • Plague (Yersinia pestis)
  • Q Fever (Coxiella burneti)
  • Sudan Ebolavirus

The Division of Well being and Social Care (DHSC), as a part of UK Vaccine Community (UKVN), has made these monetary awards to a UK Assist programme, to develop vaccines for ailments with epidemic potential in low and middle-income nations (LMICs).

The event of secure and efficacious vaccination in opposition to ailments that trigger substantial morbidity and mortality has been one of many foremost scientific advances of the twenty first century and OVG, is likely one of the world’s main tutorial vaccine analysis groups. Its present analysis contains the examine of vaccines for outbreak pathogens and pandemics and, in collaboration with Oxford’s Pandemic Sciences Institute, it attracts upon expertise and classes learnt from COVID-19 pandemic to determine and put together for future pandemic threats.

The current pandemic has highlighted the significance of constructing vaccines in opposition to potential threats to humanity and it’s in that context that we’re delighted to obtain this new funding to drive our very important analysis into vaccines to guard communities in opposition to Marburg virus, Sudan Ebolavirus, plague, Q Fever and chikungunya and mayaro virus. This important work will assist forestall future outbreaks in low- and middle-income nations and provide safety in opposition to future pandemics, as beforehand realised with the Oxford/AstraZeneca vaccine for COVID-19.”

Professor Sir Andrew Pollard, Director of OVG and the Ashall Professor of An infection and Immunity on the Pandemic Sciences Institute

Professor Teresa Lambe, Calleva Head of Vaccine Immunology on the Division of Pediatrics, and a Professor of Vaccinology and Immunology at OVG and the Pandemic Sciences Institute, mentioned: “These awards are one other necessary milestone in pandemic prevention. This funding is not going to solely help our efforts to develop life-saving safety for folks in low and middle-income nations, however will make sure the UK can reply shortly to potential future pandemic threats.”

Dr Younger Chan Kim, a Sir Henry Wellcome Fellow and Principal Investigator at OVG who shall be main the Plague, Q-fever, and Alphaviruses programmes beneath the route of Professor Pollard mentioned: “We’re thrilled to obtain these awards to develop new vaccines in opposition to these pathogens. This funding will permit us to speed up our efforts in creating reasonably priced and accessible vaccines which can be well-suited for outbreak prevention and normal immunisation in low-and-middle-income nations.”

The UKVN programme is funded by way of UK Official Improvement Help (ODA) by way of the DHSC. Awards beneath this programme have been made by way of competitions run in partnership with BBSRC, EPSRC, Innovate UK and NIHR.



Please enter your comment!
Please enter your name here